Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
At the near bottom of its range. Smart investors, long term and short term are snatching them up at these levels. They are hard to get being that so few are selling any blocks of any decent size. But hey, small, beer money blocks add up.
PWC repped investors and their representation are following EPGL closely. All are excited for EPGL's potential. Process moving slowly, as all things do. EPGL will bring justice to those who were wronged.
Great IP list for EPGL with key patents already approved for technology in the AR industry. More on the way. Not if, but when.
5 minutes of research shows just how good of startup EPGL is.
Bunnyman? Don't know of any Bunneyman Hayes within EPGL. Searched all over and found nothing.
Good accumulation this week could make for an interesting August. Progress continues for EPGL, with positive events on the horizon.
Looking good franck. Still a long ways out but they are coming. Some sooner than others. Progression is continuing as it always has.
Accumulation quietly continues. EPGL's gears are turning nicely and slowly. Progression towards industry changing patent approvals continues.
Bunnyman? Who's that. Don't see anybody within the company named Bunneyman.
Looked through company forms and see no reference to a Bunnyman Hayes.
Being that it has never happened in EPGL Meds history and shows no signs of ever occurring, there is no need to worry. Hopefully we can reach the bottom of the range again and load up yet again.
Bunnyman? Who's that?
Bunneyman?
BunneyMan? Makes no sense.
Let's see those .019's! Patents are coming, just not in short term. Those that are not patient will always sell the cheapies!
Bunnyman? Makes no sense
It's how it's kept low. So easy and inexpensive to do. Accumulation among some select traders will be done soon.
Where's it say 1 billion?
Hopefully! Patience pays off.
Fact remains! EPGL's elastic circuit patent will be be a game changer. Buyout coming soon. Not if but when. EPGL is indeed working with giants!
Looking good. More and more entities are seeing how strong EPGL really is. It couldn't be more plain as day what a good investment this is long term. I guess that's why there are so many of us accumulating.
Paul Vlassic is the main one.
The main fact is so simple. EPGL is leading the way for companies to produce flexible devices that conduct electricity with its patented Elastic Circuit technology. Creating AR products, such as smart contact lenses without EPGL's technology is going to be next to impossible and take years. As more and more of EPGL's IP continues to receive patents, they will continue to dominate the coming AR market.
Buyout is imminent. Float is disappearing quickly as accumulation remains on it's constant path upwards. As of now, being up 3000% since it's creation, Long term investors have cast their vote of trust with Hayes and company. For the small fish that were late getting into the investment, too bad for them. For short term investors praying that their timing is right, well, good luck. For all of us in the 'group', whom dominate the float, we will continue what we are doing until the main event.
Looking forward to the inevitable gains that are to come.
Pretty much just a matter of WHEN, not IF. Long term investors are ready and taking advantage of time in between.
So many possibilities when you own the leading technology such as the case with EPGL's smart lens tech. Investors know this and are loaded up, merely sitting back patiently as EPGL continues to progress. Of course, some of us are keeping the stock here until particular accumulation strategies are completed.
Investors that matter know the USPTO is a slow moving entity. Updates can happen at anytime regarding a multitude of patent apps that EPGl currently have being reviewed.
Progress and accumulation remain strong.
EPGL has been progressing as it should and that clear progression will continue. More patents approvals coming. What is deemed 'too long' by a select few, is deemed not long enough for those increasing their positions. And we are many.
Little EPGL proven to be leading all competition. Not bad for a startup that has been continually progressing since its inception.
Solid technology. Everybody can sense that EPGL is gathering steam. The dominos are about to start falling in favor of all long term shareholders that matter.
Not likely. Quite a few want it below that for the time being. Why pay high when you don't have to? Small and quiet accumulation going on right now.
Looking good. Investors that know the tech, understand the play, are locked and loaded. Company progress continues.
For the first time, EPGL reveals the "Omega" contact lens under development with InWith Corp. The patent pending "Omega" is designed to correct vision anytime by changing the curvature of the lenses on-demand, via smart phone or other mobile devices. The unique "Omega" design surrounding the iris of the eye can be seen in the AutoCAD renderings provided at www.inwithcorp.com or www.epglmed.com. The design allows both eyes to be adjusted at the same time or independently for perfected vision correction. Chips, processors and RF antennas are designed to be housed in the surrounding patented elastic circuit structure. The lenses are anticipated to be compatible with both Apple iOS and Android platforms.
EPGL owns the US patent on 3D flexible circuitry in medical device materials such as silicone hydrogel contact lenses, and the "Omega" adaptive focus device is now patent pending. The adaptive focus lens design is unique because it is designed to be scalable into current state-of-the-art mass manufacturing techniques for soft contact lenses.
EPGL was first to publicly demonstrate successful integration of patented Elastic Circuit into silicone hydrogel contact lenses, and the "Omega" lens under development will build upon this technology.
Self Focusing Via Mobile Devices
The future of human vision will include the ability to adjust vision correction on-demand and to communicate information to the eyes via mobile devices. The focal needs of the human eye are not static and can change hourly and daily due to many causes such as age, eye strain, dehydration and blood sugar levels. Current prescription optics are limited to static correction, therefore a massive new market exists for real-time vision adjustment and augmentation, enabled by new breakthrough technologies connected to mobile devices. The advent of such adjustable "Omega" lenses holds potential to disrupt the ophthalmic industry because patients could be able to adjust their vision discreetly at any time. No bulky goggles or glasses needed.
Real-time vision correction via mobile devices is coming, and InWith Corp. intends to lead the field. InWith Corp. plans to bring to market real-time, adjustable and augmented contact lenses based on EPGL technologies. The augmented vision field is estimated by some industry experts to be as high as $150 billion annually in coming years.
Starting in 2014, Dr. David Markus led pioneering R&D in world class ophthalmic facilities within the United States. This breakthrough R&D led to proof of concept for methods of integration of flexible electronics into soft contact lenses materials. As a result, the filing of IP for Elastic Circuitry, Sensor Devices, Adaptive Focus and much more, was commenced. Thus far, multiple key patents for the integration of electronic circuitry and augmentation within modern silicone hydrogel lenses, have been granted. Additionally, several more patents are pending both in the US and Internationally. Most importantly, the technologies were designed to be compatible with current mass manufacturing of contact lenses to allow scalability to the market.
Coming Soon:
Announcements from EPGL and InWith Corp. as to additional partners and relationships. Johnson & Johnson Vision Care, Inc. currently holds first right of purchase negotiation for EPGL technologies.
Amazing what Hayes and EPGL are building. Company has just about made it through the woods of being a startup and after success after success, can see the clearing. The next couple months are going to special.
Everything is timing. Hayes is building an amazing domino display. Each piece is currently being pout into place. Soon, the 1st piece will be pushed, starting a chain reaction that sends the pps skyrocketing. Be it a buyout, a partner, whatever. Its going to be good.
It's easy to see how far EPGL is set to rise after reading all the patents. Way ahead of the game where everybody else is failing. This is a 'wake up' stock. Investors will wake up to a buyout and huge increase within a short period of time.
Makes no sense. Bunny man? All one needs to do is read the patents. All public information. Epgl building steam nicely. Hopefully more losers sell.
Solid tech! Gonna be good!
Chart stronger, company progression stronger. Making those who sold early even more frustrated. Love it!
EPGL's David Markus. Progress continues. EPGL leading the way with all things AR.
Dr. David T. Markus, Ph.D. serves as a Vice President of BioMems Development at EP Global Communications, Inc. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He served as a Principal Investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macro electronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. Dr. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical.
More will be approaching the company in coming weeks.
Time will tell.